ImmunoGen, Inc.
Head Quarters
830 Winter Street USWebsite
http://www.immunogen.comIndustry
BiotechnologyEmployees
308Exchange
NASDAQImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 3 |
| Gross Margin (%) | 0.00% |
| Net Margin (%) | -0.45% |
| Returns | Stock |
| Sales | $75.00M |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | $0.00 |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 209.03 |
| EPS | -$1.00 |